Anagrelide controlled release - Sellas Life Sciences Group

Drug Profile

Anagrelide controlled release - Sellas Life Sciences Group

Alternative Names: Anagrelide CR - Sellas Life Sciences Group; CR anagrelide - Sellas Life Sciences Group; GALE-401

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioVascular
  • Developer Galena Biopharma; Sellas Life Sciences Group
  • Class 3-ring heterocyclic compounds; Antiplatelets; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Essential thrombocythaemia
  • No development reported Chronic myeloid leukaemia; Myelofibrosis; Polycythaemia vera

Most Recent Events

  • 26 Feb 2018 Sellas Life Sciences plans a phase III trial for Essential thrombocythaemia (Sellas Life Sciences pipeline, February 2018)
  • 29 Dec 2017 Galena Biopharma merged with Sellas Life Sciences and subsequently changed its name to Sellas Life Sciences Group
  • 11 Sep 2017 Galena BioPharma and BioVascular amend their license agreement for Anagrelide controlled release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top